RBC Keeps MannKind (MNKD) at 'Underperform'; Afrezza Plans in Limbo Until CCO Hired
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
MannKind (MNKD) Continues Squeezing Higher as Shorts Take Notice
March 17, 2016 2:25 PM EDTMannKind Corp. (Masdaq: MNKD) shares are continuing to see a squeeze today and have moved to session highs Thursday afternoon on strong volume.
Short interest was last at 117,258,191 shares, or about 42.7 percent of float, at the end of February. Days-to-cover is 24.7,... More
MannKind (MNKD) Posts Q4 Loss of 66c/Share
March 14, 2016 4:50 PM EDTMannKind (NASDAQ: MNKD) reported Q4 EPS of ($0.66), which may not compare with the analyst estimate of ($0.05).
Sales of Afrezza continued to be lower than expected during the fourth quarter of 2015, culminating in a decision by Sanofi on January 4, 2016 to return the... More
MannKind (MNKD) Appoints New Chief Commercial Officer; COO Martens Resigns
March 14, 2016 4:01 PM EDTMannKind Corporation (Nasdaq: MNKD) announced that Michael E. Castagna, Pharm.D., has joined the company as its Chief Commercial Officer, effective immediately. Dr. Castagna will lead commercialization efforts for Afrezza®, reporting to Matthew Pfeffer, Chief Executive Officer, and will serve on MannKinds executive leadership team.
Dr. Castagna has over 20 years of experience in healthcare, pharmaceutical, biotech and specialty pharmacy industries. He joins MannKind from Amgen, Inc., where he spent over three years as Vice President, Global Commercial Lead for a portfolio of nine biosimilar drugs, and Vice President, Global... More
